UBR5 (D6O8Z) Rabbit mAb #65344
- WB
- IP
Supporting Data
REACTIVITY | H M R Mk |
SENSITIVITY | Endogenous |
MW (kDa) | 300 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human UBR5 protein.
Background
Human E3 identified by differential display (UBR5/EDD) is a HECT domain-containing ubiquitin E3 ligase of the N-end rule pathway that promotes the ubiquitination and proteasomal degradation of proteins harboring N-degrons (1-3). UBR5 represents an ortholog of HYD, the Drosophila hyperplastic discs tumor suppressor gene product but has been found to be overexpressed in breast and ovarian cancers, suggesting a possible role in promoting tumor development (4,5). Research studies have demonstrated that UBR5 is functional within the nucleus as it participates in DNA damage signaling by controlling the activities of Chk2, TopBP1, and RNF168 (6-9). Recently, UBR5 was shown to play a novel role in immune cell function by regulating RORγt stability and IL-17 production by Th17 cells (10).
- Sriram, S.M. et al. (2011) Nat Rev Mol Cell Biol 12, 735-47.
- Callaghan, M.J. et al. (1998) Oncogene 17, 3479-91.
- Tasaki, T. et al. (2005) Mol Cell Biol 25, 7120-36.
- Clancy, J.L. et al. (2003) Oncogene 22, 5070-81.
- O'Brien, P.M. et al. (2008) Br J Cancer 98, 1085-93.
- Munoz, M.A. et al. (2007) Cell Cycle 6, 3070-7.
- Henderson, M.J. et al. (2006) J Biol Chem 281, 39990-40000.
- Honda, Y. et al. (2002) J Biol Chem 277, 3599-605.
- Gudjonsson, T. et al. (2012) Cell 150, 697-709.
- Rutz, S. et al. (2015) Nature 518, 417-21.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.